Skip to content

Stem cells in the treatment of burns

Adipose-derived Stem Cells in the treatment of Acute Burns (ASCAB) - ASCAB

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2018-002870-27-DK
Enrollment
20
Registered
2018-09-24
Start date
2018-12-11
Completion date
Unknown
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin burns. MedDRA version: 20.0 Level: LLT Classification code 10039798 Term: Second degree burns System Organ Class: 100000004863

Interventions

Product Name: Allogeneic (culture-expanded and cryopreserved) adipose-derived mesenchymal stem cells Product Code: CSCC_ASC2210 Pharmaceutical Form: Suspension for injection INN or Proposed INN: see

Sponsors

Dept. of Plastic Surgery and Burns Treatment, Copenhagen University Hospital Rigshospitalet
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Age =18 years, of either gender - Patients with deep dermal burns - The intervention must be possible to be initiated within a defined time of the acquired burn injury - Signs informed consent to participate in the study Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Previous cancer, except treated non-melanoma skin cancer - Systemic therapies altering wound healing - Known hypersensitivity to used substances - Pregnancy or breastfeeding - Incapacity to give informed consent - Withdrawal of informed consent

Design outcomes

Primary

MeasureTime frame
Main Objective: whether treatment with allogeneic adipose-derived stem cells (ASCs) can promote healing of skin burns. ;Secondary Objective: whether treatment with allogeneic ASCs can limit the extent of tissue damage of skin burns.;Primary end point(s): the burn’s degree of healing. ;Timepoint(s) of evaluation of this end point: within week 2.

Secondary

MeasureTime frame
Secondary end point(s): 2: Rate of healing 3: Microscopic examination of a biopsy 4: Blood perfusion 5: Quality of healing at outpatient follow-ups ;Timepoint(s) of evaluation of this end point: 2: within week 1. 3: within week 2. 4: serial time points within week 2. 5: within 6 months.

Countries

Denmark

Contacts

Public ContactRigshospitalet 2102

Dept. of Plastic Surgery & Burns Treatment, Copenhagen University Hospital Rigshospitalet

rikke.holmgaard@regionh.dk004535453545

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026